Development and Evaluation of a Brief Behavioral Activation Mobile Application for Nicotine Vaping Cessation Among Adolescent Primary Care Patients

针对青少年初级保健患者戒烟尼古丁的简短行为激活移动应用程序的开发和评估

• 批准号: 10250714
• 负责人: Jennifer Renee Dahne
• 金额: $ 32万
• 依托单位: MOUNTAINPASS TECHNOLOGY, LLC
• 依托单位国家: 美国
• 财政年份: 2021
• 资助国家: 美国
• 起止时间: 2021-05-01 至 2024-04-30
• 项目状态: 已结题
• 来源: https://reporter.nih.gov/project-details/10250714
• 关键词: Abstinence; Address; Adolescence; Adolescent; Age; Area; Behavior; Behavioral; Benchmarking; Cellular Phone; Clinical; Coupled; Data; Depressed mood; Development; Elements; Epidemic; Evaluation; Evidence based practice; Evidence based treatment; Feedback; Focus Groups; Funding; Goals; Health Technology; Intervention; Investigation; Life; Medical; Mental Depression; Monitor; Moods; National Institute of Drug Abuse; Nicotine; Outcome; Ownership; Patient Care; Patient Self-Report; Pediatrics; Peptide Initiation Factors; Phase; Population; Prevalence; Primary Health Care; Provider; Public Health; Randomized; Randomized Controlled Trials; Reporting; Research; Research Activity; Resources; Risk Factors; Services; Small Business Technology Transfer Research; Smoker; Smoking; Smoking Cessation Intervention; South Carolina; Surgeon; Technology; Teenagers; Testing; Time; Tobacco; Tobacco use; Training; Treatment Efficacy; United States National Institutes of Health; Universities; Work; Youth; acceptability and feasibility; arm; care providers; combustible tobacco; commercialization; comorbidity; depressive symptoms; design; efficacy evaluation; electronic cigarette use; evidence base; follow-up; high reward; high risk; improved; innovation; interest; mHealth; mobile application; nicotine use; primary care setting; programs; prospective; smoking cessation; software development; tobacco products; treatment as usual; usability; vaper; vaping; vaping nicotine

ABSTRACT The prevalence of vaping nicotine has skyrocketed among adolescents in recent years, yet no NIH-funded trials have developed or evaluated vaping cessation interventions. An ideal treatment must directly target established vaping risk factors. Depressive symptoms, which are common among adolescent vapers (36%), have recently been identified as a predominant vaping-related risk factor. The relationship between depressive symptoms and vaping is bidirectional such that depressive symptoms prospectively predict vaping initiation and sustained e- cigarette use exacerbates depression. Among smokers with depressive symptoms, tailored interventions that target both depression and tobacco use are necessary for cessation. Thus, an ideal treatment for adolescent vapers with depressive symptoms likely must also directly target depressed mood. Brief Behavioral Activation (BA) is a well-established, evidence-based treatment for depression and smoking cessation. An adapted version of Brief BA for adolescent vaping cessation could offer a promising approach to simultaneously target depressive symptoms in the service of promoting vaping cessation. To have maximum population-level impact, this intervention must be delivered via real-world clinical outlets and disseminable platforms. Primary care providers are on the front lines of adolescent vaping treatment but have limited treatment resources. Tailoring Brief BA for adolescent vaping cessation and delivery via a mobile app could offer an ideal strategy to disseminate evidence- based, depression-specific vaping cessation treatment via primary care. The goal of this high risk-high reward study is to develop, refine, and evaluate a depression-specific Brief BA for adolescent vaping cessation mobile app (“Goal2QuitVaping”). Via an established partnership between MountainPass Technology LLC and the Medical University of South Carolina, we will develop Goal2QuitVaping consistent with feedback gathered during focus groups with end-users. Software development will build upon our prior and ongoing research developing app adaptations of Brief BA for primary care depression and smoking cessation treatment. Goal2QuitVaping will subsequently be improved via iterative usability testing. We will then conduct a two-group feasibility randomized controlled trial of 1) Goal2QuitVaping vs. 2) treatment as usual for vaping cessation within primary care. Go/no go decision benchmarks for Phase II include: 1) development of Goal2QuitVaping, 2) demonstrated Goal2QuitVaping treatment feasibility and acceptability, defined as ³70% app retention across follow-up and end-user self-reported benefit of Goal2QuitVaping use, and 3) efficacy data suggesting that Goal2QuitVaping use is associated with decreases in depressive symptoms and nicotine vaping. Research activities are coupled with strong commercialization opportunities which together will propel our company toward Phase II and beyond to address the public health need for evidence-based vaping cessation interventions for adolescents.

抽象的 近年来，青少年的烟气中烟气的普遍性飙升，但没有NIH资助的试验 已经开发或评估了戒烟干预措施。理想的治疗必须直接针对建立 烟风险因素。抑郁症状在青春期中很常见（36％），最近有 被确定为主要的烟有关风险因素。抑郁症状与 蒸发是双向的，因此抑郁症状预期可以预测烟雾倡议和持续的电子 香烟使用加剧抑郁症。在有抑郁症状的吸烟者中，量身定制的干预措施 抑郁症和烟草的使用是戒烟所必需的。那是青少年的理想待遇 具有抑郁症状的蒸气可能还必须直接靶向情绪低落。简短的行为激活 （BA）是一种良好的，良好的基于​​证据的治疗抑郁和戒烟的治疗方法。适应版本 简短的青少年呕吐的BA可以提供一种有希望的方法来简单地针对抑郁症 促进戒烟的症状。为了产生最大的人口级影响，这 干预必须通过现实世界中的临床渠道和可传播的平台进行。初级保健提供者 处于青春期蒸发治疗的前线，但治疗资源有限。调整简短的ba 青少年通过移动应用程序戒烟和交付可以提供传播证据的理想策略 - 基于基于初级保健的抑郁症特异性戒烟治疗。这个高风险高奖励的目标 研究是为了开发，完善和评估针对青少年烟雾移动的抑郁症特定的简短BA App（“ goal2 quitvaping”）。通过MountainPass Technology LLC与 南卡罗来纳州的医科大学，我们将开发目标2 Quitswaping与收集的反馈一致 与最终用户的焦点小组。软件开发将基于我们先前和正在进行的研究开发 简短BA的应用程序适应初级保健抑郁症和戒烟治疗。 goal2quiting will 然后，我们将进行两组可行性随机 对照试验的1）目标2 Quitsing vs. 2）像往常一样治疗初级保健中的戒烟。去/不 II期的GO决策基准包括：1）开发目标2 QUITITing，2）证明 GOAGE2 QUITIT蒸发治疗可行性和可接受性，定义为“随访和后续”和“ 70％的应用程序保留” 最终用户自我报告的goal2 quitpiting使用的好处，以及3）效率数据，表明goal2 quitinging 使用与抑郁症状和尼古丁烟相关。研究活动耦合 凭借强大的商业化机会，将共同推动我们的公司迈向第二阶段及以后 解决公共卫生的需求，以对青少年进行基于证据的戒烟干预措施。